In fact, diverse research groups have demonstrated that GPR6 represents a possible target for the treatment of neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. The gene discussed is GPR6; the disease is early-onset autosomal dominant Alzheimer disease.